RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sio Gene Therapies - Stock

Sio Gene Therapies ROCE 2024

Sio Gene Therapies ROCE

-1.18

Sio Gene Therapies Dividend yield

Ticker

SIOX

ISIN

US8293991043

WKN

A2QHKW

In 2024, Sio Gene Therapies's return on capital employed (ROCE) was -1.18, a 246.17% increase from the -0.34 ROCE in the previous year.

Sio Gene Therapies Aktienanalyse

What does Sio Gene Therapies do?

Sio Gene Therapies Inc. is a biopharmaceutical company focused on developing gene therapies for rare genetic diseases. The company was founded in 2000 by a team of scientists specializing in the research of gene therapies for the treatment of rare diseases. Sio Gene Therapies' history began with the goal of providing an alternative treatment method for patients with rare diseases. The company focuses on the discovery and development of gene therapies based on the use of vectors to deliver genes into defective cells. The company has focused on diseases such as Huntington's chorea, Parkinson's disease, and rare hereditary diseases. Sio Gene Therapies' business model is designed to develop and market gene therapy as a novel therapy for rare diseases. The company pursues an innovative research program that aims to discover rare diseases and identify genetic mutations associated with these diseases. Sio Gene Therapies collaborates with leading scientists and research institutions to develop innovative approaches to the treatment of rare genetic diseases. Sio Gene Therapies has several divisions, including a research facility, a development department, and a sales department. Each of these departments plays a crucial role in the development of gene therapies for rare diseases. The research department identifies new target genes for the development of gene therapies, the development department develops and tests vectors for gene therapy, and the sales department works closely with physicians and health authorities to market and make gene therapy available. Sio Gene Therapies has developed a range of products based on gene therapy. This includes Axovant, a gene therapy for the treatment of Parkinson's disease that aims to deliver genes into defective cells. The drug is currently in the clinical testing stage. Peroxysome biogenesis disorder (PBD) is a rare hereditary disease caused by a dysfunction of peroxisomes. The company has already completed initial clinical studies with its product AXO-AAV-CLN6, a gene therapy approach for PBD. The results of these studies are promising, and the company is currently in Phase III of clinical studies. Sio Gene Therapies has achieved several milestones in recent years. In 2017, the company received approval from the U.S. Food and Drug Administration (FDA) for its first gene therapy for the treatment of rare degenerative retinal diseases. In August 2020, the company initiated a Phase III study for the treatment of PBD with AXO-AAV-CLN6. Overall, Sio Gene Therapies has established itself as a successful company in the gene therapy industry and has specialized in the development of gene therapies for rare genetic diseases. The company has made significant progress in the development of gene therapies in recent years and has also received important approvals from the FDA. Through ongoing research and development of new products, the company intends to contribute to the treatment and cure of rare genetic diseases in the future. Sio Gene Therapies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Sio Gene Therapies's Return on Capital Employed (ROCE)

Sio Gene Therapies's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Sio Gene Therapies's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Sio Gene Therapies's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Sio Gene Therapies’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Sio Gene Therapies Stock

What is the ROCE (Return on Capital Employed) of Sio Gene Therapies this year?

The ROCE of Sio Gene Therapies is -1.18 undefined this year.

How has the ROCE (Return on Capital Employed) of Sio Gene Therapies developed compared to the previous year?

The ROCE of Sio Gene Therapies has increased by 246.17% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Sio Gene Therapies?

A high Return on Capital Employed (ROCE) indicates that Sio Gene Therapies has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Sio Gene Therapies?

A low ROCE (Return on Capital Employed) can indicate that Sio Gene Therapies has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Sio Gene Therapies impact the company?

An increase in the ROCE of Sio Gene Therapies can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Sio Gene Therapies affect the company?

A decrease in ROCE of Sio Gene Therapies can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Sio Gene Therapies?

Some factors that can affect Sio Gene Therapies's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Sio Gene Therapies so important for investors?

The ROCE of Sio Gene Therapies is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Sio Gene Therapies take to improve the ROCE?

To improve the ROCE, Sio Gene Therapies can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Sio Gene Therapies pay?

Over the past 12 months, Sio Gene Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Sio Gene Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Sio Gene Therapies?

The current dividend yield of Sio Gene Therapies is .

When does Sio Gene Therapies pay dividends?

Sio Gene Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Sio Gene Therapies?

Sio Gene Therapies paid dividends every year for the past 0 years.

What is the dividend of Sio Gene Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Sio Gene Therapies located?

Sio Gene Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sio Gene Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sio Gene Therapies from 6/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/5/2024.

When did Sio Gene Therapies pay the last dividend?

The last dividend was paid out on 6/5/2024.

What was the dividend of Sio Gene Therapies in the year 2023?

In the year 2023, Sio Gene Therapies distributed 0 USD as dividends.

In which currency does Sio Gene Therapies pay out the dividend?

The dividends of Sio Gene Therapies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sio Gene Therapies

Our stock analysis for Sio Gene Therapies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sio Gene Therapies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.